Class 4 Risk Analysis and Post-Market Literature

1. Key takeaways

Clase 4 applies a second cumulative layer: Article 13.1 requires submission of the documents of Articles 12.1 and 12.2 with all of their items, that is, the full Clase 3 set, plus three items, namely the risk analysis and evaluation study with its risk reduction measures (13.1.1), literature reports on the use, safety and effectiveness of the product published after the product has been placed on the market (13.1.2), and the biosafety certificate for products of animal origin (13.1.3). An IVD in Clase 4 applies Articles 12.3, 12.4 and 13.1 with all of their items, pursuant to Article 13.2.

2. Legal basis

The provisions below trace the full cumulative chain for Clase 4, the three additional documents, the IVD cross-reference, and the classification rules that pull animal-origin products into the class.

3. Expert insights

Insight 1: Article 13.1.1 requires the risk documents to be prepared by the casa fabricante, the manufacturing house, not by the licence holder. This is the only limitation on the responsible party among the three additional items. The meaning is that even where the licence holder is not the manufacturer, for example a brand owner or an authorised party, the risk analysis and evaluation study with its reduction measures must still be issued by the manufacturing house. For companies supplying under ODM or OEM models, this provision makes it necessary to write the document provision obligation into the commercial contract at the contracting stage, not to discover it at dossier stage.

Insight 2: The reach of Article 13.1.2 is the post-market period, and this is the real difference in evidence type between Clase 4 and Clase 3. The literature studies required for Clase 3 under Article 12.2.5 are general literature studies; the literature reports required for Clase 4 under Article 13.1.2 must concern the use, safety and effectiveness of the product published after the product entered the market. This is in substance a real-world evidence requirement. For a product that applies for Costa Rican registration shortly after launch, the post-market data must be retrieved and organised from the marketing experience of other countries or regions.

Insight 3: Article 13.1.3 and rule 14 of Annex A echo each other and form a complete closed loop for animal-origin products. Rules 14 a) and b) place EMB containing animal cells or tissue or their derivatives, or containing products of recombinant DNA technology, directly in Clase 4, while Article 13.1.3 requires the biosafety certificate issued by the manufacturer. Articles 18.9.7 and 18.16.8 go further: when the manufacturer changes, animal-origin products must resubmit that certificate. This chain means animal-origin products cannot bypass the biosafety proof even at the change stage.

Insight 4: Rule 14 c) contains an important downward adjustment: animal-origin or recombinant DNA products that contact only intact skin are Clase 1. The rule provides that EMB containing animal cells or tissue or their derivatives, or products of recombinant DNA technology, are classified in Clase 1 where they are used only in contact with intact skin. This is a rare de-escalation clause within the Clase 4 rules, and it matters greatly for dressings and topical products containing biological components, since the classification conclusion directly determines whether the post-market literature and risk analysis requirements of Clase 4 must be met at all.

4. Practical recommendations

• Organise the Clase 4 dossier as the full Clase 3 set plus three additional items: complete Articles 12.1 and 12.2 first, then layer on Articles 13.1.1 to 13.1.3.
• Ensure the risk analysis and evaluation documents are issued by the manufacturing house under Article 13.1.1, agreeing the provision obligation and deadlines in the supply contract early.
• Retrieve and organise the post-market literature under Article 13.1.2, stating the source and publication date of each reference so as to demonstrate that it was published after marketing.
• Obtain the manufacturer-issued biosafety certificate for animal-origin or recombinant DNA products under Article 13.1.3, and resubmit it when the manufacturer changes, pursuant to Article 18.9.7.
• For animal-origin or recombinant DNA products contacting only intact skin, assess the possible Clase 1 classification under rule 14 c) to avoid over-preparing as Clase 4.

5. Verification checklist

• □ Full set of Articles 12.1 and 12.2 complete (Clase 3 baseline)
• □ Risk analysis and reduction measures documents prepared by the manufacturing house (13.1.1)
• □ Post-market literature reports retrieved with sources and dates stated (13.1.2)
• □ Manufacturer biosafety certificate obtained for animal-origin products (13.1.3)
• □ Clase 4 IVD applying Articles 12.3 and 12.4 as required by Article 13.2
• □ Rule 14 c) de-escalation possibility evaluated for products with biological components

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Costa Rican market. Our team manages Ministry of Health (Ministerio de Salud) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com